14,196 reports of this reaction
1.6% of all ASPIRIN 325 MG reports
#14 most reported adverse reaction
MYOCARDIAL INFARCTION is the #14 most commonly reported adverse reaction for ASPIRIN 325 MG, manufactured by Allegiant Health. There are 14,196 FDA adverse event reports linking ASPIRIN 325 MG to MYOCARDIAL INFARCTION. This represents approximately 1.6% of all 905,741 adverse event reports for this drug.
Patients taking ASPIRIN 325 MG who experience myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYOCARDIAL INFARCTION is a less commonly reported adverse event for ASPIRIN 325 MG, but still significant enough to appear in the safety profile.
In addition to myocardial infarction, the following adverse reactions have been reported for ASPIRIN 325 MG:
The following drugs have also been linked to myocardial infarction in FDA adverse event reports:
MYOCARDIAL INFARCTION has been reported as an adverse event in 14,196 FDA reports for ASPIRIN 325 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYOCARDIAL INFARCTION accounts for approximately 1.6% of all adverse event reports for ASPIRIN 325 MG, making it a notable side effect.
If you experience myocardial infarction while taking ASPIRIN 325 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.